Objective: Lumbar puncture (LP) is increasingly common in Alzheimer disease research; however, agreement to undergo LP varies. We sought to determine factors influencing LP consent at Alzheimer's Disease Centers (ADCs) in the United States. Results: Asians and those viewing LP negatively were less likely to agree to LP. Three hundred fifty-two participants had an LP; LP headache occurred in 11.9% (blood patch required in 1.4%) and 9.9% reported other complications. Younger individuals, women, those diagnosed with mild cognitive impairment, use of a Quincke needle, ≤ 20 mL cerebrospinal fluid drawn, and hemorrhage during LP were associated with LP headache. Use of gravity flow during LP was associated with fewer other complications (nausea, dizziness, vasovagal response, back pain, neck stiffness, and/or nerve root pain).
Statistical Analyses
We described the characteristics of individuals who completed the Patient LP Experience-Initial questionnaire, and compared the characteristics of those who did and did not agree to undergo LP using unadjusted logistic regression using generalized estimating equations, which accounts for clustering by center. Among those who underwent LP, we described individual and LP characteristics and the percent of each category experiencing LP headache or other adverse events.
We then conducted unadjusted logistic regression using generalized estimating equations to examine the associations between participant and LP characteristics and LP headache and other adverse events. Each outcome was considered in 2 separate models (LP headache: yes vs. no; other adverse events: yes vs. no). Adjusted models were used to examine the association between each participant or LP characteristic and the 2 outcomes of interest, while controlling for a continuous measure of participant age and sex. For example, for models with LP headache as the outcome, 1 model was run with participant diagnosis, age, and sex in the model, and another was run with previous LP complication, age, and sex in the model. This was repeated for all participant and LP characteristics of interest. We were unable to include multiple characteristics in the same model due to the relatively small sample size of those experiencing LP complications (N = 42 for headache; N = 35 for other adverse events). Analyses were performed in SAS version 9.4, using an α-level of 0.05 to assess statistical significance.
A small subset of the participants (n = 20) had > 1 LP Follow-up form, corresponding to having > 1 LP done. In order to ensure our analyses were conducted at the unique participant level, we restricted the analyses for these participants to their first available LP Follow-up form that corresponded closely in time to an available initial form date. We also conducted a sensitivity analysis that ignored repeated data for these participants. 
RESULTS

ADC LP Experience
ADC LP Experience surveys were completed by all ADCs active at study inception (Table 1 ). All Centers reported collecting CSF for research, with a mean of 4.4 CSF studies per Center over the previous 5 years. In addition to center-specific research, these studies included the Alzheimer's Disease Neuroimaging Initiative and clinical trials of investigational drugs. The most common CSF analytes measured were β-amyloid, tau, and 14-3-3 protein, with the last used as a marker of prion disease. 7 Discussion of LP risks and benefits with the participant required 6 to 10 minutes in 48% of ADCs, > 10 minutes in 28% of ADCs, and <5 minutes in 24% of ADCs. The most common educational material was a brochure (76% of ADCs), with a group participants' meeting being the second-most frequent (52% of ADCs). Other tools included video (36%) and webpages (20%).
Requestor LP Experience
In all, 55% of LP Requestors were physicians, 12% were nurses, and 33% were other personnel (eg, social worker). In total, 50% were women and 81% were white; 15% were Asian, 2% were African American, and 2% listed race as "other". Only 5% of LP Requestors were of Hispanic ethnicity. Only 8% of requestors had undergone LP themselves. Among those requestors who also perform LP (53.1%), the mean ± SD time since last LP performed was 0.8 ± 1.5 years.
ADC LP Requestors considered LP to be both valuable for research (5.5 ± 0.5 on a 6-point Likert scale with 6 as "extremely valuable") and associated with a relatively low amount of discomfort (2.4 ± 0.4 on a 6-point Likert scale with 1 being "no discomfort"). In comparison with colonoscopy, requestors indicated that LP causes less discomfort (2.4 ± 1.2 on a 6-point Likert scale with 1 being "much less discomfort for LP") and results in fewer complications (2.2 ± 1.0 on a 6-point Likert scale with 1 being "many fewer complications for LP").
Patient LP Experience
The Patient LP Experience queried factors influencing agreement to undergo LP, standard LP practice, and factors influencing LP complication, including LP headache. Demographic data from Patient LP Experience surveys are detailed in Table 2 . Table 3 summarizes patient and clinical characteristics and their impact on LP agreement rates. Overall, 75.5% of research participants who were invited agreed to do LP. Race, but not ethnicity, had a significant effect on agreement. Moreover, patients viewing the LP procedure as a "frightening, invasive procedure" were less likely to agree to LP.
Individuals who previously had undergone LP more often agreed to LP than individuals who had not, but this finding was not statistically significant. Furthermore, individuals with a medical history of headache were no less likely to agree to LP than those without such a history. Table 4 summarizes ADC LP practices and the characteristics of participants who had an LP. In all, 83% of LP clinicians were very experienced ( > 100 LPs performed); the amount of experience was not significantly correlated with the incidence of LP headache [unadjusted OR: 1.03; 95% confidence interval (CI): 0.98-1.09] or other mild complications (unadjusted OR: 0.93; 95% CI: 0.87-1.01). LPs were completed in 88% of those participants who initially agreed and for whom follow-up data were submitted. Several factors accounted for lack of an LP in 47 participants who initially agreed, primarily refusal after initial agreement (n = 13) or a medical reason (n = 12); not all reasons for lack of LP completion were captured.
Analyses of LP complication were conducted considering 2 parameters: LP headache and other adverse events (nausea, dizziness, vasovagal response, back pain, neck stiffness, nerve root pain). Approximately 12% of all participants with LP reported LP headache and 10% reported other adverse events. LP headaches generally were mild (64%) and lasted <1 day (40%) to 1 to 2 days (29%). A blood patch was administered in only 5 participants (1.4% of all persons undergoing LP). Nausea, dizziness, and nerve root pain each were observed in 2% of all LPs; vasovagal response, back pain, and neck stiffness each were observed in 1% of all LPs. No person reported a severe complication (eg, subdural hematoma or infection).
Previous reports have suggested several factors that contribute to incidence of LP headache and/or other LP complications. Table 5 summarizes our results regarding these factors. In the adjusted analysis, which controlled for continuous measure of age and sex, having a diagnosis of mild cognitive impairment (MCI) (vs. no MCI/dementia), having an LP performed with a Quincke needle (vs. Sprotte), and hemorrhage (defined as "initial CSF was slightly bloody") were associated with increased odds of LP headache. Having > 20 mL of CSF drawn was associated with lower odds of LP headache. Using gravity flow was associated with a lower odds of other adverse events (eg, dizziness, nausea).
In our sensitivity analysis, in which all LP Follow-ups were included for the 20 participants who had > 1 LP, CSF volume > 20 mL was not associated with lower odds of LP headache, as it was in our main analysis. Using a 24-25G needle was associated with a lower odds of LP headache. Finally, having a diagnosis of MCI was associated with an increased odds of other (nonheadache) adverse events. The correlated data for the 20 participants could not be accounted for easily in the analysis because the vast majority 
DISCUSSION Agreement to Undergo LP
Inclusion of CSF biomarkers in AD research studies, clinical trials, and clinical practice is increasingly common as their importance is accepted throughout the AD community. CSF biomarkers now are included as metrics in the NIA-Alzheimer's Association diagnostic guidelines for AD, 8, 9 as well as the International Working Group diagnostic criteria for AD. 10 However, agreement to undergo LP, even for clinical care, is not universally accepted by either physicians or patients/research participants in the United States. We therefore explored the factors influencing agreement to undergo LP in research participants at the NIA-funded ADCs (Table 3) . We found that Asian Americans agreed to LP at a lower percentage than whites; this also was true for African Americans, but the result was not statistically significant. These data demonstrate that sensitivity to racial differences is critical in increasing agreement, providing an opportunity for educational intervention. Consistent with the idea that LP education could increase participation, we found that individuals who viewed LP as a "standard medical procedure" were more likely to agree to LP than those who viewed it as a "frightening, invasive procedure". Furthermore, individuals who previously had undergone LP were more likely to agree to the current LP than those who had never undergone LP, although this did not reach statistical significance. These observations are in line with the work by Tsvetkova and colleagues who found that individuals who had an LP in the past were more likely to view LP as a standard procedure than those who had not. 11 Collectively, these data suggest that pervasive misperceptions or a lack of awareness about LP negatively impact agreement rates. Educational efforts designed to increase familiarity with and counter misinformation about LP therefore should be incorporated into AD research studies and clinical trials.
The agreement percentages included here are somewhat limited by the manner in which the survey was administered across ADCs. Centers were instructed to offer the survey to anyone being approached to consider LP, but after site-specific follow-up, we learned that some ADCs administered the survey only to participants who already had agreed to LP. This limitation means that overall LP agreement percentages are higher than would have been measured otherwise, and we cannot exclude the possibility that factors influencing LP agreement might have been subtly altered. In addition, all individuals queried about undergoing LP already were engaged in research to some degree; as such, their attitudes about LP are not reflective of the overall population.
LP Complications
Similar to many published reports, LP headache was less frequently observed with increasing age 3,12-17 and male sex [16] [17] [18] [19] (Table 5 ). LP headache also was less likely with use of the atraumatic Sprotte needle versus the cutting Quincke needle; this result is consistent with many reports, 3, 12, 14, 20, 21 and specifically with American Academy of Neurology recommendations. 22, 23 Even given these recommendations and the preponderance of research data, Quincke needles still were used in 45% of LPs (Table 4) , reflecting a reticence to change practice, which also is well documented. 20, 24, 25 We did not find a significant effect of needle gauge or patient position on LP complications. Other factors influencing LP complications have been more widely debated. We detected an effect of diagnosis with an increased incidence of LP headache for individuals with a diagnosis of MCI, but not AD dementia. It is possible that individuals with a MCI diagnosis had neuropsychiatric symptoms, including irritability or agitation, 26 thus leading to increased report of complications, but this increase was not maintained in individuals who had progressed to an AD dementia diagnosis due to decreased cognitive insight; a protective effect against LP complications previously has been reported for a diagnosis of AD or dementia. 3, 27, 28 Although anecdotal reports and some published data 29, 30 suggest that individuals who experience an LP headache are likely to have a repeat headache with subsequent LP, we did not detect an effect of a prior LP complication on LP complication incidence for the current LP. Furthermore, we did not find a significant correlation between a medical history of headache with incidence of LP headache (migraine or tension headache were listed as exemplars), as has been reported elsewhere, 3, 15 but see the work of Howell et al. 2 Lastly, we found an effect of the volume of CSF collected on LP headache; collection of > 20 mL CSF was protective (compared with ≤ 20 mL), consistent with the work of Monserrate and colleagues. 31 Higher volumes of CSF may be protective against LP headache because transiently lower CSF pressure may decrease leakage through the dural puncture, facilitating dural closure. 31 Alternatively, headache incidence may be higher in LP attempts in which complications led to early termination of the procedure, with less CSF collected.
We detected statistically significant effects of 2 factors that heretofore have received little attention in the field: method by which CSF was obtained and presence of hemorrhage during the LP. Although some practitioners are reticent to collect CSF by gravity drip due to time concerns, we found a significant correlation between use of aspiration and increased odds of other adverse events (eg, nausea, dizziness, neck stiffness). This is consistent with the report by Duits and colleagues wherein gravity drip decreased the risk for moderate to severe LP headache. 3 We also observed that the presence of hemorrhage, which was reported in 9.7% of LPs, was associated with an increased risk of LP headache, suggesting that this parameter should be closely monitored at time of LP.
Although most LP practice research focuses on post-LP headache, which was~12% in our study, 10% of participants reported other mild complications. These included nonspecific headache, nausea, dizziness, nerve root pain, vasovagal response, back pain, neck pain, and other symptoms (examples included perspiration, fatigue, and tinnitus). Of note, the percentages of nausea, dizziness, and vasovagal response were even less than those reported for venipuncture for blood sampling at 2.9% to 7.0%, 32, 33 underscoring the relative safety and tolerability of LP.
The ADC LP Experience
An added benefit of the present study is that it documents LP practices across NIA-funded ADCs. These data include reasons for acquiring CSF, demographics of LP Requestors and participants, and methods used to perform LP. Similar to the BIOMARKAPD survey, 3 all data were acquired prospectively, allowing for detailed recording of multiple parameters potentially affecting LP agreement and LP complications. The post-LP headache incidence of 11.9% and incidence of other mild adverse events of 9.9% are higher than reported by some other studies, such as Peskind and colleagues 28 and Vidoni and colleagues, 12 but well within the ranges previously reported. Across participating Centers, the BIOMARKAPD survey 3 reported a post-LP headache average incidence of 8.6% and an average incidence of other mild complications of 4.0%. Two factors to consider in both studies are: (1) no LP protocol was specified, allowing for variability among Centers and practitioners and evaluation of the impact of different techniques; and (2) a greater incidence of LP complication may have been captured because participants were systematically queried 1 week after LP, which likely uncovered complications that otherwise would not have risen to the attention of the research team or clinic.
This prospective study at NIA-funded ADCs demonstrated that LPs were safe and well tolerated, with low rates of complication. The frequencies of LP-associated nausea, dizziness, and vasovagal responses in this study were less than those that has been reported for venipuncture. 32, 33 We identified variables that can impact LP agreement rates; the observation that race and whether LP is viewed as a "standard medical procedure" affect agreement to undergo LP should caution clinicians to be sensitive to these aspects when discussing LP with patients and research participants. Given that previous LP experience increased agreement rates for subsequent LP, a ready opportunity exists to dispel LP myths and increase awareness about LP and its importance to the AD field. We also identified factors that can contribute to the incidence of LP complications. Results from this study suggest that to minimize risk of complications, including LP headache, LPs should be performed with an atraumatic (Sprotte) needle using gravity flow, with > 20 mL CSF collected. Clinicians also should be aware of the greater risk of complications in individuals who are younger, female, or have a diagnosis of MCI, or when even mild hemorrhage is observed. In contrast, medical history of headache or a prior LP complication were not associated with increased incidence of LP headache or other adverse events.
